1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Baseline characteristics of study enrollees
Variables Early (n = 128) Late (n = 52) Complete (n = 690) P Value^{^a}
Female 94 (73.4%) 34 (65.4%) 467 (67.7%) .389
Age, yr 58.0 ± 11.1 55.3 ± 12.1 58.1 ± 10.5 .330
HTN 80 (62.5%) 25 (48.1%) 375 (54.3%) .134
Hyperlipidemia 15 (11.7%) 12 (23.1%) 123 (17.8%) .126
Smoking 19 (14.8%) 6 (11.5%) 91 (13.2%) .815
Location 
    Anterior 104 (81.2%) 48 (92.3%) 650 (94.2%) 
    Posterior 24(18.8%) 4 (7.7%) 40(5.8%) <.001
Presentations 
    UIA 99 (77.3%) 38 (73.1%) 595 (86.2%) 
    SAH 29 (22.7%) 14 (26.9%) 95(13.8%) <.001
Second attempt 33 (25.8%) 7 (13.5%) 34 (4.9%) <.001
Type 
    Sidewall 66 (51.6%) 28 (53.9%) 388 (56.2%) 
    Bifurcation 62 (48.4%) 24 (46.1%) 302 (43.8%) .604
Maximum size, mm 8.3 ± 5.1 5.7 ± 2.2 4.6 ± 2.6 
Aneurysm size >7 mm 62 (48.4%) 12 (23.1%) 84 (12.2%) <.001
D/N ratio (>1) 69 (53.9%) 35 (67.3%) 391 (56.7%) .249
Balloon 22 (17.2%) 8 (15.4%) 162 (23.5%) .141
Stent 45(35.2%) 8 (15.4%) 169 (24.5%) .009
Antiplatelet medication 48 (37.5%) 19 (36.5%) 183 (26.5%) .018
Initial occlusion 
    Successful occlusion 96 (75.0%) 42 (80.8%) 519 (75.2%) 
    Residual sac 32 (25.0%) 10 (19.2%) 171 (24.8%) .661
Bioactive coil (>50%) 26 (20.3%) 8 (15.4%) 129 (18.7%) .743
Note:—D/N ratio indicates depth-to-neck ratio; HTN, hypertension; UIA, unruptured intracranial aneurysm.
↵a P < .05 is significant.